In recent years, China has carried out pragmatic cooperation in the field of traditional Chinese medicine with countries that jointly built the "Belt and Road", and has achieved positive results
in trade development, standard setting, medical care and education.
Up to now, China has built 31 national export bases for traditional Chinese medicine services, and the total export trade of traditional Chinese medicine products during the "Thirteenth Five-Year Plan" period reached 28.
19 billion US dollars
.
It is worth noting that while the export of traditional Chinese medicine products continues to grow, the internationalization process of traditional Chinese medicine products is also accelerating
.
Recently, Shanghai Hutchison Pharmaceutical's traditional Chinese medicine cholening tablets were officially shipped and will be shipped to Toronto
, Canada this week.
It is understood that bile ning tablets are Chinese patent medicine tablets made of rhubarb, knotweed, green peel, white grass root, tangerine peel, yujin, hawthorn, etc.
, which can alleviate the clinical symptoms caused by chronic cholecystitis, and have the effect
of relieving liver and choleretic, clearing heat and passing.
Since 2014, Shanghai Hutchison Pharmaceutical has begun to promote the international registration of
bile tablets.
On December 15, 2016, Cholenin tablets obtained the Canadian Natural Medicine Marketing Authorization (NPN: 80073325).
On July 12, 2019, Shanghai Hutchison Pharmaceutical Co.
, Ltd
.
obtained the certification of production sites outside Canada, becoming a Chinese traditional Chinese medicine manufacturer issued by Health Canada (FSRN: 5000525).
Previously, in October 2018, Health Canada experts came to China for academic exchanges and inspected
the production site of Shanghai Huang Pharmaceutical.
In 2022, Shanghai Hutchison Pharmaceutical cooperated with importers landing in Canada to sign a 3-year sales agreement, and in July, the two parties signed the first batch of export contracts
for Cholenic tablets.
The industry believes that as a compound Chinese medicine, this time Cholening tablets went through the approval process of European and American governments, entered the Canadian market as a drug, and took an important step
in the process of internationalization of traditional Chinese medicine.
In fact, by drawing on and integrating modern medical theories and methods, the internationalization of Chinese medicine has achieved a lot of results
in recent years.
For example, Lianhua Qingxi capsules (granules) have been registered and approved for marketing
in more than 20 overseas countries such as Indonesia, Canada, Mozambique, Romania, Thailand, Ecuador, Singapore, the Philippines, Kuwait, Mauritius, Uganda and other "botanical medicines" and "proprietary Chinese medicines".
In addition, Lianhua Qingxi capsules have also been allowed to enter designated hospitals
in Thailand, Cambodia and Indonesia.
Yiling Pharmaceutical said that the company will continue to promote the overseas registration and sales of Lianhua Qingxi in the future to further expand the overseas market share
of products.
In addition, Kangyuan Pharmaceutical's annual report also shows that it has been continuously promoting the project
of Guizhi Poria capsules to go overseas to the United States.
According to the 2019 annual report, its Guizhi Poria capsules have completed phase II.
b clinical trials in the United States and are preparing to launch phase III clinical studies, striving to make Guizhi Poria capsules obtain US FDA certification, and truly enable traditional Chinese medicine to enter the mainstream pharmaceutical market
in Europe and the United States in the form of drugs.
The "14th Five-Year Plan for the Development of Traditional Chinese Medicine" proposes to accelerate the opening and development of traditional Chinese medicine, gradually improve the relevant measures for "going out" of traditional Chinese medicine, carry out policy research on overseas markets of traditional Chinese medicine, help traditional Chinese medicine enterprises "go global", and promote the overseas registration and application
of traditional Chinese medicine products.
In this context, a large number of pharmaceutical companies are expected to join the action to promote the internationalization of Chinese medicine, and more and more Chinese medicine products will also be exported overseas to benefit the majority of overseas patients
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
